Your session is about to expire
← Back to Search
Corticosteroid
TRS01 for Anterior Uveitis
Phase 3
Waitlist Available
Research Sponsored by Tarsier Pharma
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 28 days
Awards & highlights
No Placebo-Only Group
Pivotal Trial
Summary
This trial is testing TRS01 eye drops to see if they are safe and effective for people with a type of eye inflammation called non-infectious anterior uveitis, and some of these patients may also have a related condition called uveitic glaucoma.
Eligible Conditions
- Anterior Uveitis
- Uveitic Glaucoma
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 28 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~28 days
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Anterior Chamber Cell (ACC) grade on Day 28
Secondary study objectives
Anterior Chamber Cell (ACC) grade on Day 21
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: TRS01Experimental Treatment1 Intervention
Group II: Active comparatorActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
TRS01
2021
Completed Phase 3
~150
Find a Location
Who is running the clinical trial?
Tarsier PharmaLead Sponsor
2 Previous Clinical Trials
53 Total Patients Enrolled
Lexitas Clinical TrialsStudy DirectorLexitas
Other Trials to Consider
Popular Categories
Learn More About These Treatments
Share this study with friends
Copy Link
Messenger